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C E L L  B I O L O G Y
MRNIP is a replication fork protection factor
L. G. Bennett1, A. M. Wilkie1, E. Antonopoulou1, I. Ceppi2,3, A. Sanchez2, E. G. Vernon1, 
A. Gamble1, K. N. Myers4, S. J. Collis4, P. Cejka2,3, C. J. Staples1*
The remodeling of stalled replication forks to form four-way DNA junctions is an important component of the 
replication stress response. Nascent DNA at the regressed arms of these reversed forks is protected by RAD51 and 
the tumor suppressors BRCA1/2, and when this function is compromised, stalled forks undergo pathological 
MRE11-dependent degradation, leading to chromosomal instability. However, the mechanisms regulating MRE11 
functions at reversed forks are currently unclear. Here, we identify the MRE11-binding protein MRNIP as a novel 
fork protection factor that directly binds to MRE11 and specifically represses its exonuclease activity. The loss of 
MRNIP results in impaired replication fork progression, MRE11 exonuclease–dependent degradation of reversed 
forks, persistence of underreplicated genomic regions, chemosensitivity, and chromosome instability. Our findings 
identify MRNIP as a novel regulator of MRE11 at reversed forks and provide evidence that regulation of specific 
MRE11 nuclease activities ensures protection of nascent DNA and thereby genome integrity.
INTRODUCTION
Accurate inheritance of genetic information following cell division 
depends on the fidelity of genomic DNA replication. This process is 
impaired by damage to or modification of the DNA template or by 
replisome progression through regions that are inherently difficult 
to replicate. Hence, organisms have evolved elaborate mechanisms 
to mitigate the risk of replisome collapse during replication stress (1). 
In the context of cancer treatment, many chemotherapies induce cancer 
cell death by modifying genomic DNA to induce replication fork stalling.
Mutations in the BRCA1 and BRCA2 tumor suppressor genes 
predispose individuals to breast, ovarian, and prostate cancers (2). 
Both BRCA1 and BRCA2 are crucial DNA repair factors that facilitate 
homologous recombination (HR)–mediated repair of DNA double- 
strand breaks (DSBs) (3, 4). A growing body of evidence demonstrates 
HR-independent genome maintenance functions for BRCA1/2 and 
several other core DNA repair proteins such as WRN in the protec-
tion of stalled replication forks (5–11). In response to genotoxic 
stresses, stalled replication forks remodel via rehybridization of nas-
cent DNA to form four-way DNA intermediates (12), facilitating 
tolerance or bypass of replication impediments. It is now evident 
that BRCA1/2 and RAD51 act in concert to stabilize stalled forks 
(12) and promote replication stress resistance by preventing the in-
appropriate nucleolytic degradation of reversed forks by the nucle-
ases MRE11 and EXO1 (8, 13, 14). Several recent publications have 
yielded further insight, revealing essential roles for the SMARCAL1 
chromatin remodeler, the DNA translocase ZRANB3, and even the 
RAD51 itself in replication fork reversal (12, 14–16). Loss of func-
tion of an additional subset of fork protection factors such as CtIP 
(17), BOD1L (18), ABRO1 (19), and RIF1 (20, 21) results in fork deg-
radation licensed by the nuclease DNA2.
Replication stress–induced genome instability is a major factor 
that drives cancer development and progression, and therefore, un-
derstanding the complex mechanisms at play during the replication 
stress response is an important goal. The MRE11 nuclease can act as 
either a DNA endonuclease or a 3′-5′ exonuclease, and multiple 
studies using the MRE11 inhibitor mirin implicate the exonuclease 
function of MRE11 in reversed fork degradation (4, 8). MRE11 is 
recruited to stalled forks by the enzyme PARP1 [poly(adenosine 
diphosphate)–ribose] polymerase 1] (22) in concert with the histone 
methyltransferase MLL3/4 and its binding partner, PTIP (14). How-
ever, the mechanisms governing the regulation of MRE11 activity at 
reversed forks are poorly understood, and before this study, there 
was no evidence that direct dysregulation of nuclease functions at 
reversed forks might cause pathological resection of nascent DNA 
and genome instability.
MRN-interacting protein (C5ORF45/MRNIP) was recently iden-
tified as a novel factor that promotes repair of radiation-induced 
lesions via functional interactions with the DSB-binding MRE11-
RAD50-NBS1 (MRN) complex (23). Here, we have used a combina-
tion of iPOND (isolation of proteins on nascent DNA), nuclease 
assays, and CRISPR-Cas9 and small interfering RNA (siRNA)–based 
loss-of-function studies to identify MRNIP as a novel replication fork 
protection factor. MRNIP associates with nascent DNA and promotes 
replication fork progression, resistance to replication stress agents, 
and chromosome stability. MRNIP binds directly to MRE11 and pre-
vents the MRE11 and DNA2-dependent degradation of reversed forks. 
MRNIP specifically represses MRE11 exonuclease but not endonu-
clease activity in vitro. The fork protection functions of MRNIP are 
associated with its ability to bind MRE11, because MRNIP trunca-
tions displaying reduced MRE11 interaction are unable to rescue fork 
degradation induced by MRNIP loss. In summary, our work identi-
fies MRNIP as a novel replication fork protection factor that likely 
functions by repressing the MRE11 exonuclease, and furthers our 
understanding of the molecular functions underlying the complex 
processes involved in replication fork protection.
RESULTS
Deletion of MRNIP using CRISPR-Cas9 results in  
genome instability
The novel DNA repair factor MRNIP was identified in an siRNA- based 
screen for novel regulators of genome stability and characterized as 
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a functional MRN complex interactor that promotes Ataxia 
Telangiectasia-Mutated (ATM) signaling in response to radiation- 
induced DNA damage (23). All published work on MRNIP to date 
has been based on studies using RNA interference (RNAi). We examined 
the consequences of total deletion of MRNIP using homology-directed 
repair (HDR)–directed CRISPR-Cas9 protocols. Cells were trans-
fected with Cas9 and HDR constructs expressing MRNIP-directed 
guide RNAs (gRNAs), and then insertion-positive cells were selected 
with puromycin. Surviving clones were isolated, subcultured, and 
screened for homozygous MRNIP deletion and complete loss of the 
MRNIP protein by a combination of genomic polymerase chain 
reaction (PCR), quantitative reverse transcription PCR (qRT-PCR), 
and Western blot. We successfully generated three cancer cell lines 
lacking MRNIP in two different backgrounds, hereafter referred to as 
MRNIP-A (HeLa) and MRNIP-3 or MRNIP-7 (HCT116) (Fig. 1, A and B). 
All MRNIP knockout (KO) cell lines exhibited evidence of DNA dam-
age accumulation evidenced by increased accumulation of 53BP1 and 
gH2AX-positive foci (Fig. 1, C to F) and increased neutral COMET 
score (Fig. 1G). MRNIP KO cells also displayed an increased fre-
quency of radial chromosomes and chromosome fusions (Fig. 1H). 
Levels of DNA damage were fully rescued in cell lines derived from 
MRNIP KO backgrounds engineered to stably reexpress FLAG-
tagged MRNIP (Fig. 1, E and F). The percentage of cells with damage 
foci was notably higher in MRNIP KO HCT116 relative to HeLa 
cells, and in both cases, the increase was approximately three times 
above basal levels. The ability to rescue these phenotypes by reintro-
duction of MRNIP demonstrates that the observed DNA damage in 
MRNIP KO lines is a direct consequence of MRNIP deletion and is 
not a side effect of spurious off-target Cas9 activity. Because HeLa 
cells lack functional p53, it is also clear that our observations are not 
due to selection for p53 loss of function, an effect recently observed 
in clones derived using CRISPR-Cas9 gene editing protocols (24).
MRNIP associates with active forks to promote fork 
progression and resistance to replication stress agents
We also noted a marked increase in the percentage of cells with 
more than one 53BP1-containing OPT domain (figs. S1E and S3C), 
suggesting the persistence of underreplicated DNA from the previ-
ous cell cycle. Published work suggests that accumulation of repli-
cation intermediates underpins the damage phenotypes observed in 
MRN-deficient cells (25). On the basis of these data, we decided to 
assess survival of MRNIP KO cells following treatment with replica-
tion stress agents. CRISPR-mediated deletion of MRNIP sensitized 
both cell types to the ribonucleotide reductase inhibitor hydroxyurea 
(HU), the topoisomerase I inhibitor camptothecin (CPT), and the 
DNA cross-linker mitomycin C (Fig. 2, A and B, and fig. S1, A to C). 
MRNIP KO cells also exhibited significantly increased COMET tail 
moment following HU treatment (fig. S1D). Furthermore, MRNIP 
KO cells displayed an additional elevation in gH2AX and 53BP1 foci 
following treatment with HU or CPT at doses that caused minimal 
damage in parental cells (Fig. 2C). Collectively, these data suggest 
that MRNIP functions to maintain genome stability during replica-
tion stress.
On the basis of these findings, we sought to address the mecha-
nism by which MRNIP prevents replication-associated DNA damage. 
To assess whether MRNIP associates with the replication fork, we 
carried out iPOND analyses (26). We identified endogenous MRNIP 
in iPOND eluates, but not in controls lacking the Click reagent or in 
eluates derived from cells lacking MRNIP (Fig. 2D), suggesting that 
MRNIP associates with the nascent DNA at the progressing fork. 
We also detected tagged MRNIP in iPOND eluates from HeLa cells 
stably overexpressing FLAG-MRNIP (Fig. 2E), and furthermore, 
thymidine chase resulted in loss of MRNIP in iPOND samples 
(Fig. 2E), providing additional evidence that MRNIP is a bona fide fork- 
associated protein. Addition of HU following 5-ethynyl-2’-deoxyuridine 
(EdU) labeling consistently reduced MRNIP association with the 
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Fig. 1. Genetic deletion of MRNIP using CRISPR-Cas9 results in genome insta-
bility. (A) Loss of MRNIP was confirmed by Western blotting of whole-cell extracts 
from parental HeLa and HCT116 cells and MRNIP KO CRISPR derivative lines. 
(B) Genomic DNA was isolated from lines used in (A), and PCR for the MRNIP locus 
was performed. (C and D) Parental HeLa and MRNIP KO CRISPR derivative lines 
were fixed and stained with antibodies recognizing gH2AX and 53BP1. Cells were 
counterstained with DAPI, and cells with more than five gH2AX foci were scored as 
positive. (E) Parental HeLa cells, MRNIP KO cells, and a derivative cell line stably re-
expressing FLAG-MRNIP were lysed, and proteins were resolved by SDS-PAGE and 
probed with the indicated antibodies. (F) Parental HCT116 cells, two independent 
MRNIP KO cell lines (clones 3 and 7), and a cell line derived from clone 3 stably ex-
pressing FLAG-MRNIP were treated as in (C), and cells with more than five gH2AX 
foci were scored as positive. N.S., not significant. (G) Nuclei from parental HCT116 
and HeLa and derivative MRNIP KO lines were isolated, then a neutral COMET assay 
was performed, and the results were plotted as tail moment. (H) Parental and MRNIP 
KO HCT116 cells were treated with colcemid for 3 hours, and then metaphase spreads 
were prepared and analyzed for chromosome abnormalities. The percentage of fused 
and radial chromosomes is displayed, along with representative images of abnormal 
chromosomes. Data represent the mean from three experimental repeats, and errors 
displayed represent SD (*P ≤ 0.05, **P ≤ 0.01, and ***P < 0.001 where indicated).
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fork (Fig.  2D). Examination of proteins associated with nascent 
DNA in MRNIP KO cells after 1-hour treatment with HU revealed 
no alteration in RAD51 association with nascent DNA but marked-
ly reduced levels of fork-associated proliferating cell nuclear antigen 
(PCNA) (Fig. 2D). Loss of PCNA in iPOND eluates has previously 
been attributed to fork collapse, suggesting that MRNIP is required 
to stabilize stalled replication forks (26, 27).
Therefore, we next sought to determine whether MRNIP promotes 
replication fork progression. We performed DNA fiber assays in 
growing MRNIP KO HeLa and HCT116 lines, in which nascent DNA 
was dually sequentially labeled with the nucleotide analogs CldU and 
IdU. In all clones tested, loss of MRNIP resulted in reduced replication 
fork progression, indicating the presence of replicative stress (Fig. 2, 
F and G, and fig. S2A) and suggesting that MRNIP has an important 
function at the progressing fork.
MRNIP prevents MRE11 and DNA2-dependent degradation 
of reversed forks
Given our findings, and the recent studies demonstrating a clear role 
for MRE11 in pathological resection of the regressed DNA arms of 
reversed replication forks (4, 9, 13, 14), we tested the integrity of nas-
cent DNA at stalled forks in MRNIP KO cells via a DNA fiber assay 
involving sequential CldU and IdU labeling, followed by prolonged 
fork stalling with a high dose of HU. The ratio of IdU to CldU was 
used as a readout of the extent of nascent DNA degradation. As ex-
pected, parental HeLa and HCT116 cells maintained an IdU:CldU 
ratio of approximately 1 following HU treatment (Fig. 3, A  to C). 
However, in both MRNIP-A KO HeLa and MRNIP-C3 KO HCT116 
cells, the length of the second label was significantly reduced to ap-
proximately 0.6, suggestive of extensive nuclease-mediated degra-
dation (Fig. 3, A to C). Pretreatment with the MRE11 exonuclease 
inhibitors PFM39 or Mirin or siRNA-mediated MRE11 depletion 
completely reversed replication fork degradation in HU-treated 
MRNIP KO cells (Fig. 3, A to E, and fig. S2C). Pathological fork 
degradation in MRNIP KO cells was also fully rescued by depletion 
or chemical inhibition of DNA2 (Fig. 3, D and E, and fig. S2B). In 
contrast, inhibition of the MRE11 endonuclease with either PFM01 
or PFM03 did not significantly rescue degradation in MRNIP-deficient 
cells (Fig. 3F), while, as reported previously, inhibition of either the 
MRE11 exo- or endonuclease (but not DNA2 inhibition) rescued 
degradation in BRCA2-deficient cells (Fig. 3E and fig. S4D). These 
data demonstrate that MRNIP protects replication forks specifically 
from MRE11 exonuclease–dependent degradation in multiple cell 
types. We also observed proficient chromatin loading of MRE11 in 
MRNIP-deficient cells, in contrast to the role of MRNIP previously 
observed following ionizing radiation (fig. S4A), and examination 
of MRE11 localization with EdU-labeled nascent DNA via proxim-
ity ligation assay (PLA) revealed a significantly increased associa-
tion in replication-stressed MRNIP-deficient cells (fig. S4, B and C). 
This is consistent with a model in which loss of MRNIP results in 
more persistent engagement of MRE11 with nascent DNA. In addi-
tion, replication fork degradation in MRNIP KO CRISPR-Cas9–
generated cell lines was not an off-target effect or a secondary con-
sequence of chronic DNA damage following extended periods of cell 
growth without MRNIP, as we observed fork degradation in additional 
cell lines including MCF7 breast cancer cells following transient 
depletion of MRNIP using two independent siRNA oligonucleotides 
(fig. S2D).
To gather further evidence that nascent DNA degradation in 
MRNIP KO cells occurs at the regressed arms of reversed forks in 
an MRE11-dependent manner, we depleted the fork remodeling fac-
tor SMARCAL1 and the MRE11 recruitment factor PTIP individually 
in MRNIP KO cells. Both SMARCAL1 and PTIP knockdowns sig-
nificantly rescued fork degradation associated with loss of MRNIP 
(Fig. 3, G and H). Furthermore, SMARCAL1 depletion rescued the 
increase in 53BP1 foci observed in MRNIP-depleted cells (fig. S3, A 
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Fig. 2. MRNIP associates with active forks to promote fork progression and 
resistance to replication stress agents. (A and B) Parental HeLa and HCT cells 
and MRNIP KO CRISPR derivative lines were treated with the indicated concentra-
tions of HU or CPT. After 96 hours, an MTT assay was performed, and results were 
normalized to untreated controls. (C) Parental HeLa cells and MRNIP KO CRISPR 
derivative lines were fixed and stained with an antibody recognizing gH2AX. Cells 
were counterstained with DAPI, and those with more than five gH2AX foci were 
scored as positive. (D) Parental HeLa cells and MRNIP KO CRISPR derivative HeLa 
cells were incubated with EdU for 10 min in the presence or absence of 3 mM HU. 
The iPOND protocol was then performed, and eluates were resolved by SDS-PAGE 
and blotted with the indicated antibodies. The No-Click control represents a paren-
tal untreated sample, processed in the absence of biotin azide. (E) HeLa cells stably 
expressing FLAG-MRNIP were incubated with EdU for 10 min, then the medium 
was removed, and cells were incubated in medium containing 10 mM thymidine or 
3 mM HU for the indicated times, before performing the iPOND protocol. The 
No-Click control represents the FLAG-WT untreated sample, processed in the ab-
sence of biotin azide. (F and G) Parental HeLa and HCT116 cells and MRNIP KO 
CRISPR derivative lines were labeled with CldU for 20 min and then IdU for 20 min. Green 
tracts represent CldU, and red tracts represent IdU staining—representative DNA fiber 
images are shown. Quantification of contiguous tract lengths from cells treated as in (C), 
displayed as a frequency value for each length. Data represent the mean from three ex-
perimental repeats, and the errors displayed represent SD (*P ≤ 0.05 where indicated).
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and B), suggesting that these DNA damage phenotypes are attribut-
able to pathological events occurring at reversed forks. SMARCAL1 
depletion resulted in increased gH2AX foci formation even in wild-
type (WT) cells, and it was therefore difficult to fully interpret find-
ings derived from this marker in SMARCAL1-depleted MRNIP KO 
cells. We therefore repeated the experiment in an additional cell line 
using depletion of the DNA translocase ZRANB3 to prevent fork re-
versal. Co-depletion of MRNIP and ZRANB3 resulted in a significant 
reduction in the proportion of cells with 53BP1 foci compared to 
MRNIP depletion alone, suggesting that events downstream of fork 
reversal lead to DNA damage in MRNIP KO cells (fig. S3, D and E). 
Similar findings were obtained in cells co-depleted of MRNIP and 
PTIP. SMARCAL1 and PTIP depletion also reversed the increased 
OPT domain expression observed in MRNIP-depleted cells (fig. S3C). 
Collectively, these findings suggest that MRE11 activity at reversed 
forks underpins the increase in DNA damage observed in MRNIP 
KO cells treated with replication stress agents.
Note that previous research identified a heterozygous deletion in 
MRE11 in the HCT116 cell line, which is thought to have a dominant- 
negative effect on MRN function (28, 29). However, our findings 
demonstrate that residual MRE11 exonuclease activity in HCT116 
cells is sufficient to drive replication fork degradation, and we note 
again that we observe MRE11-dependent degradation in both HeLa 
and HCT116 MRNIP KO backgrounds. Furthermore, pathological 
degradation of nascent DNA and HU sensitivity in MRNIP-deficient 
cells was rescued fully by stable reexpression of FLAG-MRNIP in 
HeLa and HCT116 MRNIP KO cell lines (figs. S2, E and F, and S5, 
B and C), indicating that this phenotype is also not an off-target con-
sequence of the CRISPR protocol.
MRNIP directly interacts with MRE11 and suppresses its 
exonuclease, but not endonuclease, activity
Given the established association between MRNIP and the MRN com-
plex, we hypothesized that MRNIP might protect nascent DNA by 
modulating MRE11 nuclease functions. First, we produced recom-
binant myelin basic protein (MBP)–tagged MRNIP (rMRNIP) in 
bacteria to allow us to assess whether MRNIP interacts directly with 
the MRE11:RAD50 (MR) complex, because our previous associa-
tion studies were limited to cell-based immunoprecipitation assays. 
Incubation of recombinant MR with MBP-MRNIP bound to amylose 
resin revealed a direct interaction between MBP-MRNIP and the 
MR complex (Fig. 4A). The MBP-only control sample did not pull 
down any detectable MR.
Spurred on by this finding, we next assessed the effect of MRNIP 
on the exonuclease activity of the MR complex against a double- 
stranded DNA (dsDNA) substrate and the endonuclease activity of 
the MRN complex against a dsDNA substrate with streptavidin- 
blocked ends (the latter in the presence and absence of a phosphorylated 
form of the endonuclease cofactor CtIP) (3). Titration of rMRNIP 
had no effect on the endonuclease activity under any condition tested 
(Fig. 4B and fig. S4E). Excitingly, however, we found that MRNIP 
specifically repressed the MRE11 exonuclease–mediated degradation 
of dsDNA (Fig. 4, C and D). This is consistent with our observation 
that degradation in MRNIP KO cells is reversible by inhibition of 
the exonuclease, but not the endonuclease, activity of MRE11.
MRNIP is a 37-kDa protein, predicted to have a small zinc finger– 
like N-terminal domain (Phyre2, SWISS-MODEL). The C terminus 
of the protein is predicted to include tracts of intrinsically disordered 
sequence, although it is possible that, on contact with a binding part-
ner, this part of the polypeptide chain assumes a more ordered struc-
ture. Both zinc fingers and intrinsically disordered proteins can 
interact with nucleic acid–mimicking PAR chains, which are formed 
by PARP at replication forks and DNA breaks (22, 30). PARP1 has 
an established role in recruitment of MRE11 to stalled replication 
forks, and PARP is also thought to regulate MRE11 function at forks 
(31). Therefore, we initially generated FLAG-tagged MRNIP mutants 
lacking the C-terminal disordered region (1 to 240, DCT from now 
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Fig. 3. MRNIP prevents MRE11 and DNA2-dependent degradation of reversed 
forks. (A to C) Parental HeLa and HCT116 cells and MRNIP KO CRISPR derivative cell 
lines were labeled with CldU for 20 min and then IdU for 20 min before the addition 
of 4 mM HU in the presence or absence of 50 mM mirin for 5 hours (see Fig. 4A). Fork 
degradation was assessed via the IdU:CldU tract length ratio. A representative set 
of DNA fibers from each condition is displayed in (A). (D) Parental HeLa and a deriv-
ative MRNIP KO cell line were transfected with a nontargeting control siRNA or an 
siRNA targeting either MRE11 or DNA2. After 48 hours, cells were treated as in (A), 
and the IdU:CIdU tract length ratio for each condition is shown. (E) MRNIP-A KO or 
BRCA2 KO HeLa cells were labeled as in (A) and then cotreated with 4 mM HU and 
either DMSO, PFM39, or DNA2 inhibitor for 5 hours. Fork degradation was assessed 
via the IdU:CldU tract length ratio. (F and G) MRNIP KO HeLa cells were transfected 
with a nontargeting control siRNA or siRNAs targeting either PTIP or SMARCAL1. 
After 48 hours, cells were labeled with CldU for 20 min and then IdU for 20 min be-
fore the addition of 4 mM HU for 5 hours. Fork degradation was assessed via the 
IdU:CldU tract length ratio. (H) Cells were transfected as in (A) and then lysed, and 
the extracts were resolved by SDS-PAGE followed by blotting with the indicated 
antibodies. Data represent the mean from three experimental repeats, and the er-
rors displayed represent SD (*P ≤ 0.05 and **P ≤ 0.01 where indicated).
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on) or the N-terminal region predicted to form a zinc finger (63 to 
343, DNT from now on) in the GateWay system and used these con-
structs to derive stable cell lines expressing truncated proteins in the 
MRNIP KO HeLa background. FLAG immunoprecipitations in 
MRNIP KO cells expressing these mutants revealed that both the N 
terminus and the C terminus of MRNIP are important for MRNIP 
interaction with MRE11 (Fig. 4E). We note, however, that neither 
deletion causes a complete loss of MRE11 interaction, suggesting 
that MRNIP may contact MRE11 via multiple binding surfaces. 
Restoration of WT MRNIP expression in MRNIP KO cell lines con-
sistently and fully rescued the fork degradation phenotype (Fig. 4F). 
However, neither the DNT or DCT truncation significantly rescued 
this phenotype (Fig. 4F), implying that the MRNIP-MRE11 interac-
tion is important for fork protection.
Given the newly identified role of MRNIP in fork protection and 
the requirement for the MRNIP N-terminal domain, we hypothe-
sized that MRNIP is co-recruited to forks with MRE11 via an inter-
action between the predicted NTD zinc finger motif and PAR chains. 
We therefore mutated all four cysteine residues (C4A mutant) pre-
dicted to coordinate a metal ion within the zinc finger–like struc-
ture (fig. S5, A and B). However, analysis of fork integrity in MRNIP 
null cells stably expressing FLAG-C4A MRNIP revealed that the pre-
dicted zinc finger motif of MRNIP is not required to mediate fork 
protection, implying that although this domain does form in vivo, it 
is not important for the function of MRNIP in replication fork pro-
tection (fig. S5B). Likewise, the S115A and D25 mutants of MRE11 
were fully proficient in fork protection (fig. S5C), despite being in-
volved in radioresistance (23). This is further evidence that MRNIP 
functions at forks and DSB breaks via very distinct mechanisms. Col-
lectively, our data support a role for MRNIP as a novel fork-associated 
factor that protects newly formed DNA from pathological degrada-
tion, likely by repressing the exonuclease activity of MRE11.
DISCUSSION
The reversal of replication forks to form Holliday junction–like four- 
way DNA intermediates is now well established as an important re-
sponse to diverse genotoxic stresses (12, 32). Our data indicate that 
the novel DNA repair factor MRNIP binds directly to MRE11, where 
it functions to protect reversed replication forks from pathological 
MRE11-dependent degradation, likely via repression of the MRE11 
exonuclease. MRNIP loss sensitizes multiple cancer cell lines to replica-
tion stress agents and chemotherapies. We also present evidence that 
MRNIP loss results in elevated DNA damage and chromosomal instability.
Consistent with a protective role for MRNIP at reversed forks, 
we find that the degradation of nascent DNA and increased DNA 
damage observed in MRNIP KO cells are mitigated by SMARCAL1 
depletion. We also provide several lines of evidence for MRE11 in-
volvement in this process. First, small-molecule inhibitors of MRE11 
exonuclease activity rescue degradation in MRNIP KO lines, and fur-
thermore, depletion of MRE11 itself or the MRE11 fork recruitment 
factor PTIP also fully rescued the degradation phenotype.
Our confirmation that MRNIP could interact directly with the 
MR complex note is also in keeping with the immunoprecipitation 
procedures used to monitor MRE11-MRNIP association, which were 
all performed following extensive benzonase digestion, suggesting that 
the MRE11-MRNIP interaction is not mediated via indirect DNA 
binding. In addition, we also previously observed that expression of a 
nuclear localization sequence (NLS) mutant of MRNIP results in re-
localization of the MRN complex to the cytosol (23), suggestive of 
direct interaction. It is possible that the association between MRNIP 
and nascent DNA is mediated via MRE11.
Depletion or chemical inhibition of DNA2 also completely res-
cued degradation in MRNIP KO cells. DNA2 is a 5′-3′ nuclease/
helicase with important roles in DSB resection and Okazaki fragment 
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Fig. 4. MRNIP directly interacts with MRE11 and suppresses its exonuclease, 
but not endonuclease, activity. (A) Recombinant MBP or recombinant MBP-tagged 
MRNIP was bound to amylose resin and then incubated for 3 hours with recombinant 
MR complex. Unbound material was washed away, and bound proteins were eluted 
using 20 mM maltose. Samples were denatured and resolved via SDS-PAGE followed 
by blotting with the indicated antibodies. Input proteins (50 ng) are shown as a 
gauge of stochiometry. (B) Endonuclease assay with MRN (30 nM), pCtIP (60 nM), 
and various concentrations of MRNIP (30, 60, 90, and 120 nM) on a 5′ end-labeled 
70–base pair (bp)–long dsDNA blocked at both ends with streptavidin. Red asterisk 
indicates the position of the labeling. (C) Exonuclease assay with MR (20 nM) and 
various concentrations of MRNIP (30, 60, and 120 nM) on a 5′ end-labeled 50-bp-
long dsDNA. Red asterisk indicates the position of the labeling. (D) Quantitation of 
the assay shown in (C). nt, nucleotides. (E) MRNIP KO HeLa cells and derivative cell 
lines stably expressing FLAG-tagged WT MRNIP or N-terminally truncated (63–343) 
or C-terminally truncated (1–240) MRNIP were lysed, and FLAG immunoprecipita-
tion was performed followed by elution with 3× FLAG peptide. Inputs and eluates 
were resolved by SDS-PAGE followed by Western blotting with the indicated anti-
bodies. (F) Identical cell lines to (A) were plated and labeled with CldU for 20 min 
and then IdU for 20 min before the addition of 4 mM HU for 5 hours. Fork degrada-
tion was assessed via the IdU:CldU tract length ratio. Data represent the mean from 
three experimental repeats, and the errors displayed represent SD (*P ≤ 0.05 and 
**P ≤ 0.01 where indicated).
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maturation (33), which acts in concert with WRN in the degra-
dation of reversed replication forks (34) even in cells proficient in 
RAD51 filament formation. This model suggests that DNA2 and 
MRE11 function in separate pathways of fork degradation (34). Re-
cent studies have also demonstrated that both MRE11- and DNA2- 
dependent degradation can be modulated by depletion of RADX, a 
negative regulator of RAD51 (10, 11). Our findings constitute the 
first report of MRE11- and DNA2-dependent fork degradation—a 
scenario that might be unique to MRNIP-deficient cells. It is possi-
ble that dysregulation of MRE11 exonuclease activity in MRNIP- 
deficient cells results in unique intermediates that are dependent on 
the nuclease activity of DNA2 for continued processing. Given that 
MRE11 is a relatively slow exonuclease, it is possible that initial re-
section by MRE11 is a precursor to continued processing by more 
processive exonucleases such as DNA2. EXO1/MRE11 interplay at 
forks and breaks is well established (13, 35, 36). Degradation in 
MRNIP KO cells proceeds in a strictly MRE11 exonuclease–dependent 
manner, in contrast to BRCA2 KO cells where coordinated endo- 
and exonuclease activities drive degradation.
MRNIP is a relatively small protein with no obvious enzymatic 
functions. Nonetheless, both N- and C-terminal truncations of MRNIP 
exhibit reduced interaction with MRE11, and mutants lacking these 
regions cannot rescue fork degradation induced by MRNIP loss. 
MRNIP is predicted to contain a zinc finger–like N-terminal domain 
and an unstructured C-terminal domain. Both of these structural fea-
tures are capable of binding to PAR chains at stalled forks (13) and 
DNA breaks (22, 30). This was intriguing, given the known role of 
PARP1 in recruitment of MRE11 to stalled replication forks. How-
ever, alanine substitution of all four predicted metal ion–coordinating 
cysteine residues did not compromise interaction with MRE11, and 
furthermore, the quadruple mutant protein retained full function-
ality in replication fork protection. This suggested that the MRNIP- 
MRE11 interaction is largely independent of PARP function, and 
this was confirmed by olaparib treatment (data not shown). Here, 
we also established that two MRNIP mutants that are unable to rescue 
radiosensitivity phenotypes are fully proficient in fork protection. 
This suggests that MRNIP is differently regulated in each scenario, 
in that both kinase inputs and key sequence features involved in pro-
moting DSB repair have no apparent role at reversed forks. Hopefully, 
future investigations into the structure of MRNIP bound to the MR 
complex will prove revealing in this regard.
Last, a recent study has demonstrated a role for the yeast homolog 
of ATM (Tel1) in protecting replication forks from nuclease-mediated 
degradation (37). Given that MRE11 phosphorylation by ATM on 
Ser676 and Ser678 functions to repress resection at DSBs (38), and based 
on our previous observation that MRNIP promotes damage-induced 
ATM activation, it is tempting to speculate that MRNIP promotes 
MRE11 phosphorylation by ATM [or another phosphatidylinositol-3 
kinase-related kinase (PIKK)] during replication stress to limit resec-
tion at reversed replication forks. This is the subject of further study in 
the Staples laboratory. In conclusion, we have identified MRNIP as 
a novel replication fork protection factor, which prevents nuclease- 
mediated degradation of stalled forks.
MATERIALS AND METHODS
Cell culture and CRISPR-Cas9 cell line generation
U2OS, MCF7, BRCA2 KO HeLa (a gift from the Moldovan Laborato-
ry, Penn State), HeLa, and HCT116 Flp-In TREX cancer cells were 
maintained as adherent monolayers in Dulbecco’s modified Eagle’s 
medium  (DMEM) with 10% fetal bovine serum at 37°C in an atmo-
sphere of 5% CO2. Stable MRNIP KO CRISPR clones were created 
using Santa Cruz Biotechnology CRISPR-Cas9 and HDR plasmids 
(sc-412131-KO-2 and sc-412131-HDR-2), using the manufacturer’s 
protocol. In brief, cells were seeded in six-well plates and transfected 
with the relevant plasmids using Lipofectamine 2000. The following 
day, the cells were reseeded into 10-cm plates in the presence of 
puromycin (2 mg/ml). After a further 10 days, individual clones 
were picked, subcultured, and analyzed by genomic PCR, qRT-
PCR, and Western blotting to confirm homozygous genetic dele-
tion of MRNIP.
Stable cell line generation
Stable HeLa and HCT116 Flp-In cell lines expressing doxycycline- 
inducible FLAG-MRNIP (WT protein and relevant mutants) were 
generated via cotransfection with pObpA-Flp recombinase and ei-
ther empty pDEST-Flag/FRT/TO or pDEST-Flag/FRT/TO-MRNIP 
according to the Flp-In manufacturer’s instructions (Invitrogen). 
Clones stably expressing FLAG-MRNIP were selected in medium 
containing blasticidin S (15 mg/ml) and hygromycin B (200 mg/ml) 
(Invitrogen). Expression was tested by addition of doxycycline (1 mg/ml) 
for 24 hours and Western blotting with anti-FLAG and anti-MRNIP 
antibodies.
RNAi transfections
MCF7, U2OS, HeLa, and HCT116 cells were transfected with 10 to 
50 nM siRNA using Lipofectamine RNAiMAX (Invitrogen) accord-
ing to the manufacturer’s instructions. Cells were collected, lysed, 
or fixed for analysis after 48 hours unless otherwise indicated.
Cell lysis and Western blotting
For the preparation of whole-cell extracts, cells were solubilized in 
lysis buffer [25 mM tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton 
X-100, 1 mM dithiothreitol (DTT), and 1 mM MgCl2] supplemented 
with benzonase (50 U/ml) (Novagen) and cOmplete protease inhib-
itors and PhosSTOP phosphatase inhibitors (Roche). Lysates were 
clarified by centrifugation at 16,000g for 15 min at 4°C. Gel electro-
phoresis was performed using 4 to 15% Mini-PROTEAN TGX pre-
cast gels (Bio-Rad). Briefly, samples were resolved in TGX running 
buffer and transferred to polyvinylidene difluoride (PVDF) mem-
branes, which were then probed for the protein of interest using 
antibodies diluted in phosphate-buffered saline (PBS)–0.1% Tween 
20 (Sigma-Aldrich) containing 5% Marvel.
Immunoprecipitation
To purify FLAG-tagged proteins, 1 mg of the whole-cell extract was 
incubated with 20 ml of M2-anti FLAG beads (Sigma-Aldrich) for 
16 hours at 4°C. For immunoprecipitations using antibodies raised 
against endogenous proteins, 2 to 5 mg of antibody were incubated 
with the sample for 1 to 2 hours before addition to 20 ml of washed 
protein G beads (Santa Cruz Biotechnology) and incubation for 
16 hours at 4°C. Beads were then pelleted and washed three times in 
25× bed volume of the lysis buffer. The bound protein was eluted 
either by heating the beads at 95°C for 5 min with 2 × Lithium 
dodecyl sulphate (LDS) buffer (Invitrogen) or by incubation with 
3 × FLAG peptide (100 ng/ml) (Sigma-Aldrich) according to the 
manufacturer’s instructions. Inputs represent 5% of the extract used 
for the immunoprecipitation.
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Immunofluorescence
Cells were grown on glass coverslips in 24-well trays, transfected/
treated as indicated, fixed with either methanol or 3% buffered para-
formaldehyde for 10 min at room temperature, and permeabilized 
in PBS containing 0.5% Triton X-100 for 5 min at room tempera-
ture. Cells were incubated with primary antibody overnight in the 
cold room and detected using a secondary Alexa Fluor 488– or Alexa 
Fluor 594–conjugated goat anti-rabbit or anti-mouse immuno-
globulin G fluorescent secondary (Invitrogen). Antibody dilutions 
and washes after incubations were performed in PBS. DNA was coun-
terstained with 4′,6-diamidino-2-phenylindole (DAPI) (1 mg/ml), and 
coverslips were mounted cell-side down in Shandon Immu-Mount 
medium (Thermo Fisher Scientific). Fluorescence microscopy was 
performed on a Zeiss LSM710 confocal microscope at ×40 or ×63 
magnification. Images were captured and analyzed using Zen soft-
ware (Zeiss).
Metaphase spreads
Cells were treated with 4 mM HU for 4 hours and released for 18 hours 
into fresh HU-free medium. Four hours before fixation, colcemid 
(100 ng/ml) (Sigma) was added to the cells, which were subsequently 
collected, washed in PBS, and resuspended in 5 ml of hypotonic 
solution (10 mM KCl) for 10 min at 37°C. Cells were fixed in cold 
fixation buffer (3:1 methanol/acetic acid). Cells were centrifuged, 
and the pellets were washed three times with cold fixative before 
spreading the chromosomes by dropping on cold slides. The slides 
were air-dried overnight and mounted with Antifade Mounting 
Medium containing DAPI (1 mg/ml). Fifty metaphases per sample 
were scored per sample in each experiment.
Survival assays
Cells were plated in six-well plates at a density of 100,000 cells per 
well and then transfected with the appropriate siRNAs if required. 
After 48 hours, cells were replated on 96-well plates at a density of 
2000 cells per well, and the following day, these were treated as required, 
in quadruplicate. After a further 96 hours, 3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) reagent was added 
to the cells at a final concentration of 1 mg/ml, and these were incu-
bated at 37°C for 3 hours. The medium was removed and replaced 
with 200 ml of dimethyl sulfoxide (DMSO) to solubilize the formazan 
product, and the absorbance of this product was assessed by quantify-
ing optical density at 540 nm using a spectrophotometric microtiter 
plate reader. Results were normalized to untreated controls.
iPOND
iPOND was performed on HeLa cells exactly as described previously 
by Sirbu and colleagues (26, 27, 39). Briefly, newly synthesized DNA 
was labeled with 10 mM EdU for 10 min, cells were fixed in 1% form-
aldehyde and permeabilized, and the click reaction was performed 
using azide–polyethylene glycol biotin conjugate (Click Chemistry 
Tools). Cell preparations were then sonicated and EdU-labeled DNA 
was precipitated using streptavidin beads, before washing and elu-
tion in loading buffer containing 1 mM DTT.
DNA fiber assay
Cells were plated and transfected if appropriate, pulse-labeled with 
25 mM CldU (Sigma-Aldrich) and 250 mM IdU (Sigma-Aldrich) for 
20 min each, and then treated with HU (4 mM) for 5 hours if required. 
The cells were resuspended in PBS at 7.5 × 105 cells/ml. Then, 2.5 ml 
of cells was mixed with 7.5 ml of lysis buffer [200 mM tris (pH 7.5), 
25 mM EDTA, and 0.5% SDS] on a clean slide (Thermo Fisher Sci-
entific). After 7 min, the slides were tilted at 25° and then air-dried, 
before fixation in methanol/acetic acid (3:1). DNA fibers were de-
natured using 2.5 M HCl for 75 min and then washed extensively 
with 1× PBS before blocking in 1% bovine serum albumin (BSA)/
PBS containing 0.2% Tween 20 for 1 hour. CldU- and IdU-labeled tracts 
were incubated with two anti-BrdU (5-bromo-2′-deoxyuridine) anti-
bodies [one specific for CldU (Abcam) and the other for IdU (BD)], 
washed, and incubated with goat anti-mouse/rat Alexa Fluor 488 and 
Alexa Fluor 594 (Invitrogen). DNA fibers were visualized on a Zeiss 
LSM710 confocal microscope, and images were collected using Zen 
software and then analyzed with ImageJ.
Neutral COMET assays
Glass slides (Thermo Fisher Scientific) were prepared by adding 800 ml 
of molten normal melting point agarose (1%) to a slide followed by 
setting of the gel underneath a coverslip and overnight air drying. 
Following the appropriate treatment, exponentially growing cells 
were trypsinized and diluted to a density of 1 × 105 cells/ml. Low–
melting point agarose (1% at 37°C) was then added to cells, mixed 
and added to a normal melting point agarose (NMPA)–coated 
slide, and covered by coverslip and left on ice for 2 min. Coverslips 
were then removed and placed in Coplin jars containing fresh neu-
tral lysis buffer (2.5 M NaCl, 100 mM EDTA, 10 mM tris base, and 
1% N-lauroylsarcosine; buffer pH was adjusted to 9.5)—cells were 
lysed for 1 hour at 4°C. Slides were then washed three times in fresh 
cold 1× tris-borate-EDTA (TBE) (10 min per wash), transferred to an 
electrophoresis tank, covered with cold electrophoresis buffer, and 
subjected to an electrophoretic current of 25 V for 25 min. Slides 
were then removed from the tank, washed with cold 1× PBS three 
times for 5 min each, and air-dried overnight. Slides were rehydrat-
ed in dH2O for 30 min, and SYBR Gold was added to each slide—
excess stain was removed, and slides were air-dried overnight be-
fore analysis/storage.
In vitro MBP pulldowns
Amylose magnetic beads (NEB) (100 ml) were washed three times in 
wash buffer [50 mM tris (pH 7.4), 1 mM DTT, 10% glycerol, and 
120 mM NaCl] and then split into two batches, and 5 mg of either 
MBP or MBP-MRNIP was bound to each set of beads via incuba-
tion in the cold room for 1 hour with rotation. Beads were then 
washed three times in lysis buffer and resuspended in 1 ml of wash 
buffer containing 1 mg of recombinant MR. This was incubated for 
3 hours in the cold room with rotation, and then the beads were washed 
five times and bound proteins were eluted using 20 mM maltose.
Recombinant protein production
Recombinant MR was produced by the Cejka laboratory, via expres-
sion in Spodoptera frugiperda 9 (Sf9) cells, and purified as described 
previously (40).
Recombinant MBP-tagged MRNIP was produced as follows. 
Briefly, the MRNIP open reading frame (ORF) was amplified using 
the following primers: MRNIP-F, 5′-ATATGGATCCGCGTCGC-
TTCAGCGTTCTCGGG-3′; MRNIP-R, 5′-GCATCCATGGTCA-
CACATCATCGAAGTCTTCC-3′. The PCR product was digested 
with Bam HI and Nco I and cloned into Bam HI and Nco I sites of 
pMALT-P-MBP (a gift from the Cejka laboratory) generating 
pMALT- P-MBP-MRNIP. MRNIP was expressed in Escherichia coli 
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BL21(DE3)pLysS One Shot (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. MBP-MRNIP was extracted from 
E. coli cell pellets with lysis buffer [50 mM tris-HCl (pH 7.5), 1 mM 
phenylmethyl sulfonyl fluoride (PMSF), 1 mM dithiothreitol (DTT), 10% 
glycerol, and 500 mM NaCl] and sonicated. MBP or MBP- MRNIP 
protein was bound to amylose resin (NEB) and eluted using 10 mM 
maltose. Purified MBP-MRNIP was loaded on a pre-equilibrated 
16/600 HiLoad Superdex 75 pg column (GE Healthcare) using gel 
filtration buffer [50 mM tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 
10% glycerol, and 1 mM DTT], and fractions were collected and then 
analyzed using SDS–polyacrylamide gel electrophoresis (PAGE) and 
Coomassie staining. Peak fractions were then pooled and concentrated.
DNA substrates and nuclease assays
The DNA substrates for the in vitro assays were used and radio-
actively labeled as described previously (41).The endonuclease assays 
with MRN, phosphorylated CtIP, and MRNIP were carried out in a 
15-ml volume. They were assembled on ice in reaction buffer con-
taining 25 mM tris-acetate (pH 7.5), 1 mM DTT, 5 mM magnesium 
acetate, 1 mM manganese acetate, 1 mM adenosine triphosphate 
(ATP), pyruvate kinase (80 U/ml) (Sigma-Aldrich), 1 mM phospho-
enolpyruvate, BSA (0.25 mg/ml) (New England Biolabs), and 1 nM 
oligonucleotide–based DNA substrate (in molecules). Biotinylated 
DNA ends were blocked by adding 15 nM streptavidin and incubat-
ing the samples for 5 min at room temperature. The reaction was 
then returned on ice, where recombinant proteins were added. The 
reactions were incubated for 2 hours at 37°C and stopped by adding 
0.5 ml of proteinase K (14 to 22 mg/ml) (Roche) and 0.5 ml of 0.5 M 
EDTA for 30 min at 50°C. The stopped reactions were mixed with 
an equal volume of loading dye [95% formamide, 20 mM EDTA, 
and bromophenol blue (1 mg/ml)] and boiled for 4 min at 95°C. The 
reaction products were separated by denaturing electrophoresis on 
15% polyacrylamide gels (acrylamide:bisacrylamide, 19:1; Bio-Rad) 
containing 7 M urea. Radioactively labeled low–molecular weight 
marker (Affymetrix, J76410) was used where indicated. The samples 
were separated by electrophoresis in 1× TBE buffer (89 mM tris, 
89 mM boric acid, and 2 mM EDTA), and the resolved gels were fixed 
in fixing solution (40% methanol, 10% acetic acid, and 5% glycerol) 
for 30 min at room temperature. The gels were then dried, exposed 
to storage phosphor screen, and scanned by a Typhoon imager (GE 
Healthcare). Quantitations were carried out using ImageJ software.
Differently from above, 5 nM oligonucleotide–based substrate 
(in molecules) was used for the exonuclease assays, and after addi-
tion of the proteins, reactions were incubated for 1 hour at 37°C. 
Stopping, reaction product separation, and analysis were performed 
as described for the endonuclease assays.
Proximity ligation assays
Cells were plated onto circular sterile coverslips in 24-well plates 
and grown for 24 hours. Cells were pretreated with 10 mM EdU for 
20 min or pretreated with EdU for 20 min followed by a 2-hour 
treatment with 5 mM HU at 37°C. Cells were washed in 1× PBS 
before permeabilization (20 mM NaCl, 0.5% Triton X-100, 3 mM 
MgCl2, 300 mM sucrose, and 10 mM Pipes) for 5 min on ice. Cells 
were washed in 1× PBS before fixation in 4% paraformaldehyde in 
PBS for 10 min on ice. One further wash in 1× PBS was carried out 
before blocking in 5% BSA in PBS overnight at 4°C.
The click reaction (10 mM biotin azide, 2 mM CuSO4, and 10 mM 
sodium ascorbate in 1× PBS) was carried out on all samples pre-
treated with EdU as well as a “No-EdU” control that was included 
for each cell line. Briefly, cells were washed in 1× PBS before incu-
bation for 1 hour at room temperature in either 200 ml of the Click 
reaction solution or the DMSO “No-Click” solution. Cells were washed 
in 1× PBS, and then the PLA assay (Sigma Duolink) was carried out 
according to the manufacturer’s instructions. Briefly, samples were 
incubated with rabbit anti-biotin (Bethyl, A150-109A: 1:3000) and 
mouse anti-MRE11 antibodies (Abcam, ab214: 1:100) in Duolink 
antibody dilution buffer at 37°C in a humidified chamber for 1 hour. 
Cells were then washed in Duolink buffer A and incubated with anti- 
rabbit Plus and anti-mouse minus PLA probes for 1 hour at 37°C. 
Ligase was then added and incubated for 30 min at 37°C. Cells were 
washed in buffer A, and then fluorescence signal was amplified by the 
addition of Duolink polymerase for 100 min at 37°C (in a dark humidified 
box). Cells were then washed in Duolink buffer B and finally in 0.01× 
buffer B. PLA foci were visualized on a Zeiss LSM710 confocal micro-
scope, and images were captured using Zen software (Black edition).
Primers
The following primers were used: MRNIP Genomic Forward, GGT-
GGGAAGAGAAAAGCACTT; MRNIP Genomic Reverse, CAACA-
CATGCTACAGAACCACTAG; MRNIP GW FOR 63-343, GGGG-
ACAAGTTTGTACAAAAAAGCAGGCTTGCAGGGACAAGT; 
MRNIP GW REV STOP, GGGGACCACTTTGTACAAGAAAGCT-
GGGTTCACACATCATCATCGAAGTC; MRNIP FOR GW, GG-
GGACAAGTTTGTACAAAAAAGCAGGCTTGGCGTC-
GCTTCAGCGTTCTCGTTCAGAGC; MRNIP GW REV 1-240, 
G G G G A C C A C T T T G T A C A A G A A A G C T G G G T T C A T -
GAACTTTTTCTAGGTGGC; C3134AA FOR, AAGAGTGTCA-
AGTGGACAGCCAAAGCTGCTGGAGAGAAGCAGTCC; 
CC1215AA REV, TGCGCCTGGAAGAGGCGGGCGCTGCAGG-
CGCGTAGCACCCGAGAA; CC3134AAC REV, GGACTG CTTC-
TCTCCAGCAGCTTTGGCTGTCCACTTGACACTCTT; 
CC1215AA FOR, TTCTCGGGTGCTACGCGCCTGCAGCGCCC-
GCCTCTTCCAGGCGCA.
siRNA oligonucleotide sequences
All siRNAs were purchased from MWG Eurofins, high-performance 
liquid chromatography (HPLC)–purified, and synthesized with dTdT 
overhangs. The oligonucleotide sequences used are as follows: Mrnip-1, 
5′-GCAAACAGCCUUCAUCCAA-3′; Mrnip-2, 5′-GUUAGGAG-
GGACAGGGUUC-3′; Smarcal1, 5′-GCUUUGACCUUCUUAGCAA-3′; 
Ptip, 5′-UGUUUGCAAUUGCGGAUUAUC-3′; and Zranb3, 5′- 
GAUCAGACAUCACACGAUU-3′.
List of antibodies
The following antibodies were used: Western blotting: MBP 
(Abcam, ab40390), MRE11 (GeneTex, 12D7), RAD50 (Bethyl, 
A300-184A), MRNIP (Abcam, C terminus, ab150917, 1:1000), actin 
(Abcam, ab1801), tubulin (Abcam, ab4074), SMARCAL1 (Santa Cruz 
Biotechnology, sc-376377), PTIP (Bethyl, A300-370A), RPA (Abcam, 
ab2175), gH2AX (Cell Signaling Technology, 9718), H2A (Abcam, 
ab18255), and FLAG-HRP (Sigma-Aldrich, A8592); immunofluores-
cence: 53BP1 (Abcam, ab21083, 1:2000) and gH2AX (Upstate, 1:1000).
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/28/eaba5974/DC1
View/request a protocol for this paper from Bio-protocol.
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